1304 related articles for article (PubMed ID: 26566863)
21. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
23. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
[TBL] [Abstract][Full Text] [Related]
24. Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.
Beier D; Schulz JB; Beier CP
Mol Cancer; 2011 Oct; 10():128. PubMed ID: 21988793
[TBL] [Abstract][Full Text] [Related]
25. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
26. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
28. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
29. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
30. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
Munoz JL; Walker ND; Scotto KW; Rameshwar P
Cancer Lett; 2015 Oct; 367(1):69-75. PubMed ID: 26208431
[TBL] [Abstract][Full Text] [Related]
31. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Lan F; Pan Q; Yu H; Yue X
J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.
Beier D; Schriefer B; Brawanski K; Hau P; Weis J; Schulz JB; Beier CP
J Neurooncol; 2012 Aug; 109(1):45-52. PubMed ID: 22544650
[TBL] [Abstract][Full Text] [Related]
33. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Fukushima T; Takeshima H; Kataoka H
Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
[TBL] [Abstract][Full Text] [Related]
34. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
35. PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
Yuan AL; Meode M; Tan M; Maxwell L; Bering EA; Pedersen H; Willms J; Liao J; Black S; Cairncross JG; Blough MD
J Neurooncol; 2020 Jul; 148(3):463-472. PubMed ID: 32562246
[TBL] [Abstract][Full Text] [Related]
36. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Beier D; Röhrl S; Pillai DR; Schwarz S; Kunz-Schughart LA; Leukel P; Proescholdt M; Brawanski A; Bogdahn U; Trampe-Kieslich A; Giebel B; Wischhusen J; Reifenberger G; Hau P; Beier CP
Cancer Res; 2008 Jul; 68(14):5706-15. PubMed ID: 18632623
[TBL] [Abstract][Full Text] [Related]
38. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
[TBL] [Abstract][Full Text] [Related]
39. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Tiek DM; Rone JD; Graham GT; Pannkuk EL; Haddad BR; Riggins RB
Sci Rep; 2018 May; 8(1):7222. PubMed ID: 29740146
[TBL] [Abstract][Full Text] [Related]
40. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F
Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
